跳至主要内容
临床试验/NCT07305480
NCT07305480进行中(未招募)不适用

Longitudinal Observational Study for Developing and Validating a Digital Twin Model of Human Blastocyst Development, Implantation Potential, and Pregnancy Outcomes Using Fully De-Identified, Multimodal IVF Clinical and Molecular Data

Ukraine Association of Biobank1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2023年1月2日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
1
试验地点
1
主要终点
Accuracy of Digital Twin Model in Predicting Embryo Implantation

研究概览

简要总结

This study aims to develop and validate a non-image, multimodal digital twin model of the human blastocyst using fully de-identified clinical, laboratory, molecular, biochemical, and long-term follow-up data obtained during routine IVF treatment. The dataset includes parental clinical background, IVF cycle parameters, embryo morphology in text format, PGT-A results, secretome and exosomal biomarkers, endometrial receptivity profiles, pregnancy course, delivery outcomes, and child development data up to 3 years of age.

The purpose of this observational study is to create a longitudinal reference dataset linking embryo-level molecular and biochemical characteristics with clinical outcomes from implantation to early childhood. The digital twin model is intended to investigate predictors of implantation success, embryo viability, and early developmental trajectories without the use of images or videos. No investigational drugs or devices are used, and no procedures beyond standard clinical practice are added.

详细描述

This observational study collects and integrates multimodal, non-image data from routine IVF cycles to construct digital twin models of human blastocysts. The dataset includes synchronized molecular, cellular, biochemical, and clinical parameters describing both the embryo and the maternal environment during implantation and early pregnancy. All information is fully de-identified and obtained as part of standard clinical care.

Parental and Clinical Background

The dataset incorporates:

demographic factors, reproductive history, and relevant risk factors;

karyotype results, thrombophilia and autoimmune screening;

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • Women undergoing in vitro fertilization (IVF) treatment at participating fertility clinics.
  • Availability of non-image embryo development data.
  • Availability of text-based morphological embryo descriptions.
  • Availability of PGT-A results.
  • Availability of secretome and exosomal biomarker data.
  • Availability of molecular and biochemical data collected during routine clinical care.
  • Availability of IVF cycle parameters collected during routine clinical workflow.
  • Embryos evaluated according to standard clinic protocols with documented implantation outcomes.
  • Age of the oocyte provider between 20 and 42 years.
  • Signed informed consent allowing use of fully de-identified clinical, laboratory, molecular, and follow-up data.

排除标准

  • Embryos lacking sufficient non-image developmental data required for digital twin generation or implantation outcome assessment.
  • Use of donor oocytes or donor embryos when linkage with required clinical or laboratory metadata is not possible.
  • Cases in which implantation outcome cannot be confirmed.
  • Presence of severe uterine abnormalities prior to embryo transfer that may affect implantation reliability.
  • Withdrawal of consent for use of anonymized clinical, laboratory, or follow-up data.

结局指标

主要结局

Accuracy of Digital Twin Model in Predicting Embryo Implantation

时间窗: From embryo transfer (Day 0) to confirmation of clinical pregnancy (up to 12 weeks of gestation).

Evaluation of the predictive performance of the digital twin model for embryo implantation outcomes based on integrated multi-omics, morphokinetic, and clinical data. The accuracy will be measured by AUC, sensitivity, specificity, and calibration metrics against real clinical implantation outcomes.

次要结局

未报告次要终点

研究者

发起方
Ukraine Association of Biobank
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
不适用
A First in Human, Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Total Daily Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Intravenous Infusion of OMN6 in Healthy Subjects
NL-OMON51720Omnix Medical104
已完成
1 期
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled,Single and Multiple Ascending Intravenous Dose Study toAssess the Safety, Tolerability, Pharmacokinetics of VGL101 in HealthyAdults
ACTRN12622000933752Vigil Neuroscience, Inc60
招募中
1 期
A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CAN10, an Anti-IL1RAP Monoclonal Antibody, in Healthy Subjects and in Subjects with Mild to Moderate Plaque PsoriasisPlaque psoriasis
2023-504450-35-00Cantargia AB112
已完成
1 期
A study to investigate the safety and concentration in the blood and urine of different dose strengths of OCT461201 in healthy volunteers
ISRCTN39003837Oxford Cannabinoids Technologies Ltd.32
进行中(未招募)
1 期
Assess the effect of switching HIV-1 infected subjects with CNS toxicity (= Grade 2) from ATRIPLA™ or its components to MK-1439AHuman Immunodeficiency Virus-1 infectionMedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2015-003617-18-IEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.86